Bladder Cancer, Kidney Cancer, Cancer Genetics, Cancer Immunotherapy.
B.A. Economics and Biology: Wesleyan University, 1992; MD: Brown University School of Medicine, 1996; Intern/Resident: Beth Israel Hospital, 1996-1999; Clinical Fellow: Dana-Farber / Partners Cancer Care, 1999-2002; Postdoctoral Fellow: Dana-Farber Cancer Institute and Harvard Medical School, 2000-2005; Instructor in Medicine: University of North Carolina, School of Medicine, 2005-2007; Assistant Professor: University of North Carolina, 2007-2013; Associate Professor of Medicine: University of North Carolina, 2013-2018; Professor of Medicine: University of North Carolina, 2018-present.
Research and Clinical Interests
The Kim Lab is focused on understanding the genetic and epigenetic events involved in the initiation and progression of renal cell carcinoma (RCC) and bladder cancer and their relationship to anti-tumor immunity. Through NextGeneration sequencing of primary human tumors and the use of genetically engineered mouse models (GEMMs), as well as in vitro systems, our goal is to identify the critical genomic and epigenetic changes that are drivers of RCC and bladder cancer. Our ultimate goal is to elucidate the functional consequences of these genomic events in order to pinpoint novel, high impact therapeutic targets for therapy.
William Y. Kim, MD, is a UNC Lineberger Comprehensive Cancer Center member and Distinguished Professor of Medicine and Genetics in the Department of Medicine and Division of Hematology and Oncology at UNC-Chapel Hill. Kim is involved with Cancer Genetics, Clinical Research, Urologic Oncology Program and the Cancer Genetics Program. The Kim Lab studies the genetics of bladder and kidney cancers.